Skip to Content

Ofatumumab

In the US, Ofatumumab (ofatumumab systemic) is a member of the following drug classes: CD20 monoclonal antibodies, selective immunosuppressants and is used to treat Chronic Lymphocytic Leukemia and Multiple Sclerosis.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XC10

CAS registry number (Chemical Abstracts Service)

0679818-59-8

Chemical Formula

C6480-H10022-N1742-O2020-S44

Molecular Weight

146060

Therapeutic Categories

Antineoplastic agent

Anti-CD20 monoclonal antibody

Chemical Name

Immunoglobulin G1, anti-(human CD20 (antigen))(human monoclonal HuMax-CD20 heavy chain), disulfide with human monoclonal HuMax-CD20 kappa-chain, dimer (WHO )

Foreign Names

  • Ofatumumabum (Latin)
  • Ofatumumab (German)
  • Ofatumumab (French)
  • Ofatumumab (Spanish)

Generic Names

Brand Names

  • Arzerra
    GlaxoSmithKline, Finland; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Singapore; GlaxoSmithKline Brasil, Brazil; GlaxoSmithKline Export, Serbia; Novartis, Argentina; Novartis, Brazil; Novartis, Denmark; Novartis, Estonia; Novartis, Ireland; Novartis, Japan; Novartis, Lithuania; Novartis, Norway; Novartis, Poland; Novartis, Sweden; Novartis, Slovakia; Novartis, United States; Novartis Europharm, Greece; Novartis Europharm, Romania; Novartis Europharm, Slovenia; Novartis Europharm Limited, Iceland; Novartis Europharm Limited, Netherlands; Novartis Farmaceutica, Spain; Novartis Pharmaceuticals, Australia; Novartis Pharmaceuticals, Canada; GlaxoSmithKline GSK, Oman
  • Arzerra 1000mg
    GlaxoSmithKline, Israel; Novartis, France; Novartis, Hungary; Novartis Europharm, Austria; Novartis Pharma, Germany; Novartis Pharmaceuticals UK, United Kingdom
  • Arzerra 1000mg/50ml
    Novartis Pharma, Switzerland
  • Arzerra 100mg
    GlaxoSmithKline, Israel; Novartis, France; Novartis, Hungary; Novartis Europharm, Austria; Novartis Pharma, Germany; Novartis Pharmaceuticals UK, United Kingdom
  • Arzerra 100mg/5ml
    Novartis Pharma, Switzerland

Glossary

TermDefinition
BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.